文献速递血栓与止血

利伐沙班治疗儿童静脉血栓栓塞:EINSTEIN-Jr 三期剂量-暴露-反应评估

Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation.
PubMed 文献 · J Thromb Haemost · 2020-06-04

基于 EINSTEIN-Jr 随机研究,对 335 例 0-17 岁接受利伐沙班治疗的儿童 VTE 患者进行群体药代动力学建模,316 例(94.3%)可评估。利伐沙班暴露在成人暴露范围内,各 PK 参数与疗效、出血或不良事件结局无聚集性关联,片剂与混悬液结果相似,体重调整方案获验证。

要点

  • 利伐沙班体重调整方案在儿童 VTE 中暴露达成人范围。
  • PK 参数与复发 VTE、出血或不良事件无聚集性关联。
  • 片剂与口服混悬液疗效安全性结果相似,混悬液接受度良好。

核心结论

  • 体重调整的儿童利伐沙班方案(片剂或混悬液)获验证,可适当治疗儿童 VTE。

研究设计与样本

  • 基于 EINSTEIN-Jr 随机研究,对 335 例 0-17 岁接受利伐沙班的儿童 VTE 患者,其中 316 例(94.3%)可评估 PK。
  • 采用稀疏血采样和群体 PK 建模,推导每日 AUC(0-24)ss、稳态谷浓度 Ctrough,ss 和峰浓度 Cmax,ss。

主要发现

  • 利伐沙班暴露在成人暴露范围内。
  • 各 PK 参数与复发 VTE、重复影像学结局、出血或不良事件无聚集性关联。
  • 片剂与混悬液结果相似,混悬液接受度和适口性良好。

关键数值与推荐

  • 体重≥30 kg 每日一次,≥12 至<30 kg 每日两次,<12 kg 每日三次。
  • ≥20 kg 儿童方案已确认,<20 kg 仅预测。

临床怎么用

  • 儿童 VTE 可按体重选择利伐沙班片剂或混悬液,每日一至三次给药。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, the randomized EINSTEIN-Jr study showed similar efficacy and safety for rivaroxaban and standard anticoagulation for treatment of pediatric venous thromboembolism (VTE). The rivaroxaban dosing strategy was established based on phase 1 and 2 data in children and through pharmacokinetic (PK) modeling. METHODS: Rivaroxaban treatment with tablets or the newly developed granules-for-oral suspension formulation was bodyweight-adjusted and administered once-daily, twice-daily, or thrice-daily for children with bodyweights of ≥30, ≥12 to <30, and <12 kg, respectively. Previously, these regimens were confirmed for children weighing ≥20 kg but only predicted in those <20 kg. Based on sparse blood sampling, the daily area under the plasma concentration-time curve [AUC(0-24)ss ] and trough [Ctrough,ss ] and maximum [Cmax,ss ] steady-state plasma concentrations were derived using population PK modeling. Exposure-response graphs were generated to evaluate the potential relationship of individual PK parameters with recurrent VTE, repeat imaging outcomes, and bleeding or adverse events. A taste-and-texture questionnaire was collected for suspension-recipients. RESULTS: Of the 335 children (aged 0-17 years) allocated to rivaroxaban, 316 (94.3%) were evaluable for PK analyses. Rivaroxaban exposures were within the adult exposure range. No clustering was observed for any of the PK parameters with efficacy, bleeding, or adverse event outcomes. Results were similar for the tablet and suspension formulation. Acceptability and palatability of the suspension were favorable. DISCUSSION: Based on this analysis and the recently documented similar efficacy and safety of rivaroxaban compared with standard anticoagulation, we conclude that bodyweight-adjusted pediatric rivaroxaban regimens with either tablets or suspension are validated and provide for appropriate treatment of children with VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020. PMID: 32246743. doi:10.1111/jth.14813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。